A Phase 1 Dose Escalation Study of TTI-237 Administered Intravenously Every 3 Weeks in Subjects With Advanced Malignant Solid Tumors
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary purpose is to address the safety and tolerability of TTI-237. Patient will be assessed on an ongoing basis during their participation on the trial.
Wyeth is now a wholly owned subsidiary of Pfizer
United States: Food and Drug Administration
|Phoenix, Arizona 85012|
|Fountain Valley, California 92708|
|Baltimore, Maryland 21287|